FindTrial
Sign In

Single Dose Versus Double Dose Tamsulosin in Management of Moderate and Severe LUTS Due to BPH

Single Dose Versus Double Dose Tamsulosin in Management of Moderate and Severe Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05834270
Enrollment
60
Registered
2023-04-28
Start date
2022-05-01
Completion date
2022-12-01
Last updated
2023-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Disease, Prostate Hypertrophy, Prostate Obstruction, Prostatic Neoplasms

Keywords

Tamsulosin, Prostate

Brief summary

Single dose versus double dose tamsulosin in Management of Moderate and severe lower urinary tract symptoms due to benign prostatic hyperplasia

Interventions

DRUGSingle dose tamsulosin 0.4mg

Single dose tamsulosin 0.4mg

DRUGDouble dose tamsulosin 0.4mg

Double dose tamsulosin 0.4mg

Sponsors

Menoufia University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
MALE
Age
50 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* age more than 50 years * moderate to severe lower urinary tract symptoms

Exclusion criteria

* prostatic cancer * urethral stricture * prostate surgery * Neurogenic bladder

Design outcomes

Primary

MeasureTime frameDescription
Change in the lower urinary tract symptoms3 monthsAssessed by the improvement in the internal prostatic symptoms score (IPSS)

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026